Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts.
The stock seems poised for a recovery due to the Austedo franchise, the improved positioning of the U.S. generics business and a better capital structure, according to Piper Sandler.
The Teva Pharmaceutical Industries Analyst: David Amsellem upgraded the rating for Tel Aviv-Yafo, Israel-based Teva from Neutral to Overweight, while raising the price target from $12 to $19.
Check out other analyst stock ratings.
The Teva Pharmaceutical Industries Thesis: The Austedo franchise is well positioned due …
Full story available on Benzinga.com